Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
EKSO Ekso Bionics Holdings Inc
- Stocks
- Healthcare
- NASDAQ: EKSO
Price (delayed)
$4.36
Market cap
$8.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.35
Enterprise value
$6M
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Founded in 2005, Ekso
Highlights
EKSO's EPS is up by 49% year-on-year and by 13% since the previous quarter
The net income has grown by 24% YoY and by 4.7% from the previous quarter
EKSO's quick ratio is down by 15% YoY and by 7% QoQ
Ekso Bionics Holdings's equity has decreased by 10% YoY
Key stats
What are the main financial stats of EKSO
Market
Valuations
Earnings
Shares outstanding
1.94M
Market cap
$8.44M
Enterprise value
$6M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
0.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.34
Revenue
$17.54M
Gross profit
$9.37M
Operating income
-$10.64M
Net income
-$10.79M
EBIT
-$10.51M
EBITDA
-$8.93M
Free cash flow
-$8.38M
Per share
Balance sheet
Liquidity
EPS
-$7.35
EPS diluted
-$7.35
Free cash flow per share
-$4.95
Book value per share
$7.67
Revenue per share
$10.36
TBVPS
$13.33
Total assets
$27.31M
Total liabilities
$14.62M
Debt
$5.62M
Equity
$12.69M
Working capital
$11.52M
Debt to equity
0.44
Current ratio
2.35
Quick ratio
1.7
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
-50.9%
Gross margin
53.4%
Net margin
-61.5%
Operating margin
-60.7%
Return on assets
-39.2%
Return on equity
-82.5%
Return on invested capital
-76.8%
Return on capital employed
-56%
Return on sales
-59.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EKSO stock price
How has the Ekso Bionics Holdings stock price performed over time
Intraday
-1.13%
1 week
-3.11%
1 month
-39.78%
1 year
-74.05%
YTD
-52.35%
QTD
-27.81%
Financial performance
How have Ekso Bionics Holdings's revenue and profit performed over time
Revenue
$17.54M
Gross profit
$9.37M
Operating income
-$10.64M
Net income
-$10.79M
Gross margin
53.4%
Net margin
-61.5%
EKSO's operating income is up by 24% year-on-year
The net income has grown by 24% YoY and by 4.7% from the previous quarter
The net margin is up by 23% YoY and by 2.7% QoQ
EKSO's operating margin is up by 22% YoY but it is down by 3.9% QoQ
Price vs fundamentals
How does EKSO's price correlate with its fundamentals
Growth
What is Ekso Bionics Holdings's growth rate over time
Valuation
What is Ekso Bionics Holdings stock price valuation
P/E
N/A
P/B
0.57
P/S
0.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.34
EKSO's EPS is up by 49% year-on-year and by 13% since the previous quarter
EKSO's P/B is 72% below its 5-year quarterly average of 2.0 and 53% below its last 4 quarters average of 1.2
Ekso Bionics Holdings's equity has decreased by 10% YoY
The stock's price to sales (P/S) is 84% less than its 5-year quarterly average of 2.7 and 53% less than its last 4 quarters average of 0.9
Ekso Bionics Holdings's revenue has decreased by 2.1% from the previous quarter and by 2.1% YoY
Efficiency
How efficient is Ekso Bionics Holdings business performance
EKSO's return on sales is up by 23% year-on-year and by 2.9% since the previous quarter
The ROIC has grown by 22% YoY
The ROA has grown by 15% YoY and by 3.2% from the previous quarter
The ROE has grown by 14% YoY and by 2.3% from the previous quarter
Dividends
What is EKSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EKSO.
Financial health
How did Ekso Bionics Holdings financials performed over time
Ekso Bionics Holdings's total assets is 87% more than its total liabilities
The current ratio has declined by 16% year-on-year and by 6% since the previous quarter
EKSO's quick ratio is down by 15% YoY and by 7% QoQ
The debt is 56% lower than the equity
The debt is down by 18% YoY and by 6% QoQ
Ekso Bionics Holdings's equity has decreased by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.